期刊文献+

COPD合并TB患者血清IgM、IgG、IgA含量的临床分析 被引量:2

Clinical Analysis of COPD and TB Patient Serum IgM, IgG, IgA Content
下载PDF
导出
摘要 目的研究慢性阻塞性肺疾病(COPD)合并肺结核(TB)时血清中免疫球蛋白Ig M、Ig G、Ig A含量变化。方法选取在我院就诊的慢性阻塞性肺疾病(COPD)合并肺结核(TB)的患者(试验组),以及单纯慢性阻塞性肺疾病(COPD)和单纯肺结核(TB)还有正常健康人(健康对照组)的体液免疫功能进行对比分析。观察Ig M、Ig G、Ig A含量。结果四组间比较,Ig M均无统计学意义,Ig A:试验组高于COPD组、试验组高于健康对照组、TB组高于COPD组、TB组高于健康对照组、差异有高度统计学意义。Ig G:试验组高于COPD组,TB组高于COPD组,差异有高度统计学意义。结论当COPD合并TB患者Ig G和Ig A水平均明显升高,这种情况可能对COPD合并TB患者是一种保护作用。 Objective To investigate the changes of IgM, IgG, IgA in patients who with lung tuberculosis complicated by chronic obstructive pulmonary disease(COPD). Methods Select COPD complicated with TB named observation group, patients with COPD, patients with TB and health people, investigate the changes of IgM, IgG, IgA. Results Comparison between the four groups, IgM had no statistical significance. IgA Observation group batter than the COPD group, observation group batter than the health group, TB group batter than the health group. IgG observation group batter than the COPD group, TB group batter than the COPD group. Conclusion When lung tuberculosis complicated by chronic obstructive pulmonary disease IgG and IgA were elevated, This may be a protective effect in patients.
作者 胡晓慧 张萍
出处 《中国医药指南》 2016年第1期108-109,共2页 Guide of China Medicine
关键词 COPN合并TB 免疫球蛋白 COPD complicate with TB Immunoglobulin
  • 相关文献

参考文献3

二级参考文献86

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2周玉民,王小平,曾祥毅,丘蓉,谢俊芬,刘升明,郑劲平,钟南山,冉丕鑫.茶碱治疗慢性阻塞性肺疾病的随机双盲平行对照研究[J].中华结核和呼吸杂志,2006,29(9):577-582. 被引量:44
  • 3Centers for Disease Control and Prevention ( CDC ). Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal Wkly Rep, 2007, 56:250-253.
  • 4Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 2006, 368 : 1575-1580.
  • 5Shah NS, Wright A, Drobniewski F, et al. Extreme drug resistance in tuberculosis (" XDR-TB "): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis, 2005,9 Suppl 1 :S77.
  • 6Hohz TH, Riekstina V, Zarovska E, et al. XDR-TB : extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000-2002. Int J Tubere Lung Dis, 2005, 9 Suppl 1 : S258.
  • 7Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep, 2006,55:301-305.
  • 8Centers for Disease Control and Prevention ( CDC ). Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal Wkly Rep, 2007, 56:250-253.
  • 9Banerjee R, Allen J, Westenhouse J, et al. Extensively drug- resistant tuberculosis in california, 1993-2006. Clin Infect Dis, 2008,47:450-457.
  • 10Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis, 2007, 13:380-387.

共引文献8319

同被引文献20

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部